A Study of Toripalimab in Adjuvant Therapy After Resection of High-risk Renal Cancer Tumors
Status:
RECRUITING
Trial end date:
2025-03-03
Target enrollment:
Participant gender:
Summary
This is a phase II study to investigate the effect of treprolizumab on tumor control and survival in high-risk renal cancer after radical nephrectomy. Patients will be treated with treprolizumab, which will be administered every 3 weeks until tumor recurrence or intolerable toxicities